- Home
- SLRN vs TRML Comparison
SLRN vs TRML Comparison
Compare SLRN & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRN
- TRML
- Stock Information
- Founded
- SLRN 2020
- TRML 2021
- Country
- SLRN United States
- TRML United States
- Employees
- SLRN N/A
- TRML N/A
- Industry
- SLRN Biotechnology: Pharmaceutical Preparations
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- SLRN Health Care
- TRML Health Care
- Exchange
- SLRN Nasdaq
- TRML Nasdaq
- Market Cap
- SLRN 485.6M
- TRML 419.1M
- IPO Year
- SLRN 2023
- TRML N/A
- Fundamental
- Price
- SLRN $4.37
- TRML $22.88
- Analyst Decision
- SLRN Buy
- TRML Strong Buy
- Analyst Count
- SLRN 6
- TRML 3
- Target Price
- SLRN $11.50
- TRML $65.00
- AVG Volume (30 Days)
- SLRN 463.0K
- TRML 175.8K
- Earning Date
- SLRN 11-13-2024
- TRML 11-07-2024
- Dividend Yield
- SLRN N/A
- TRML N/A
- EPS Growth
- SLRN N/A
- TRML N/A
- EPS
- SLRN N/A
- TRML N/A
- Revenue
- SLRN N/A
- TRML N/A
- Revenue This Year
- SLRN N/A
- TRML N/A
- Revenue Next Year
- SLRN N/A
- TRML N/A
- P/E Ratio
- SLRN N/A
- TRML N/A
- Revenue Growth
- SLRN N/A
- TRML N/A
- 52 Week Low
- SLRN $3.36
- TRML $12.12
- 52 Week High
- SLRN $8.89
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- SLRN 31.17
- TRML 39.23
- Support Level
- SLRN $4.29
- TRML $25.58
- Resistance Level
- SLRN $6.19
- TRML $27.51
- Average True Range (ATR)
- SLRN 0.45
- TRML 1.72
- MACD
- SLRN -0.20
- TRML -0.55
- Stochastic Oscillator
- SLRN 6.39
- TRML 8.34
About SLRN ACELYRIN INC.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.